Suppr超能文献

肿瘤相关抗原作为实体癌治疗性抗体合适靶点的条件。

Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers.

作者信息

Kurosawa Y

机构信息

Institute for Comprehensive Medical Science, Fujita Health University , Toyoake, Aichi 470-1192, Japan.

出版信息

J Stem Cells Regen Med. 2011 Apr 1;7(1):14-28. doi: 10.46582/jsrm.0701003. eCollection 2011.

Abstract

Since the success of rituximab and trastuzumab for treatment of non-Hodgkin's lymphoma and breast cancer, respectively, a huge therapeutic potential of monoclonal antibodies (mAbs) was realized and development of therapeutic mAbs has been widely tried against various cancers. However, the successful examples are still limited and therapeutic mAbs are not yet available for the majority of human cancers. We established a procedure for comprehensive identification of tumor-associated antigens (TAAs) through the extensive isolation of human mAbs that may become therapeutic. Thirty-twoTAAs have been identified and 555 mAbs that bound to one of the TAAs have been isolated to date. Now we are trying to select TAAs as proper targets for therapy and candidate mAbs as drugs from among them. The immunohistochemical analysis using many fresh lung cancer specimens suggested probabilities of proper targets, and moreover, presence of cancer-specific epitopes that could be distinguished from normal epitopes on the same molecules by mAbs. For Abs to efficiently kill the cancer cells they should have the ability to induce immunological cytotoxicity such as ADCC and/or CDC. They should also be able to inhibit the function mediated by the target Ags. For clinical point of view, the continuous presence of the target molecule on the cell surface until cell death might be essential for successful treatment. Therefore, it will be required for targets TAAs to play essential roles in tumorigenesis. Otherwise the cancer cells that do not express them could selectively survive during treatment and finally become dominant. It was also suggested that even the same molecules could play different roles in tumorigenesis quite often in different patients. Therefore when we develop therapeutic Abs, we should obtain information about the conditions of patients including genetic background to whom the treatment will be effective. I will discuss how we can accomplish this purpose.

摘要

自从利妥昔单抗和曲妥珠单抗分别成功用于治疗非霍奇金淋巴瘤和乳腺癌以来,单克隆抗体(mAb)的巨大治疗潜力得以实现,针对各种癌症的治疗性单克隆抗体的研发也得到了广泛尝试。然而,成功的例子仍然有限,大多数人类癌症仍无法使用治疗性单克隆抗体。我们建立了一种程序,通过广泛分离可能具有治疗作用的人源单克隆抗体来全面鉴定肿瘤相关抗原(TAA)。迄今为止,已鉴定出32种TAA,并分离出555种与其中一种TAA结合的单克隆抗体。现在我们正试图从这些TAA中选择合适的治疗靶点,并从其中挑选候选单克隆抗体作为药物。使用许多新鲜肺癌标本进行的免疫组织化学分析表明了合适靶点的可能性,此外,还存在癌症特异性表位,单克隆抗体可以将其与同一分子上的正常表位区分开来。为了使抗体有效地杀死癌细胞,它们应具有诱导免疫细胞毒性的能力,如抗体依赖的细胞介导的细胞毒性(ADCC)和/或补体依赖的细胞毒性(CDC)。它们还应能够抑制由靶抗原介导的功能。从临床角度来看,直到细胞死亡时靶分子在细胞表面持续存在对于成功治疗可能至关重要。因此,靶点TAA需要在肿瘤发生中发挥重要作用。否则,不表达它们的癌细胞在治疗期间可能会选择性存活并最终占主导地位。还表明,即使是相同的分子,在不同患者的肿瘤发生中也常常发挥不同的作用。因此,当我们开发治疗性抗体时,我们应该获取有关患者状况的信息,包括治疗有效的患者的遗传背景。我将讨论我们如何能够实现这一目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d8/3908282/65ed70a33450/jsrm-07-019-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验